Stoke Therapeutics
STOK30.0101.80% ( +0.530 )
Stoke Therapeutics (STOK)
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its propr...
- Open
- 29.250
- High
- 30.090
- Low
- 28.920
- Prev. Close
- 29.480
- Volume
- 689.48K
- Turnover
- 20.51M
- Avg Price
- 29.746
- Bid/Ask Ratio
- --
- Amplitude
- 3.97%
- 52wk High
- 40.220
- Volume Ratio
- 0.73
- Turnover Ratio
- 1.47%
Stoke Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$45.8252.52%
Forecast & RatingStrong buy
13analysts
- Strong buy92.31%
- Buy7.69%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 27 at 03:01 PM
Stoke Therapeutics schedules webcast, call on Q2 business and financial update
- PUBT · Jul 17 at 03:33 PM
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement
- PUBT · Jul 13 at 06:31 AM
Stoke Therapeutics names Thomas McCauley chief scientific officer
- Simplywall · Jul 10 at 08:17 AM
Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?
- Simplywall · Jul 7 at 07:05 PM
How Investors May Respond To Stoke Therapeutics (STOK) Completing Phase 3 Enrollment For Zorevunersen In Dravet Syndrome
- PUBT · Jul 6 at 03:11 PM
Stoke Therapeutics CMO Barry Ticho disposes of common shares worth $235,889.32
